Despite growing mosquito resistance to insecticides, vector control remains the main way of preventing and reducing malaria transmission, says the WHO in its recently released World Malaria Report 2016.

‘Long-lasting insecticidal nets are the mainstay of malaria prevention’, said Secretary General, Margaret Chan, adding that the WHO recommends their use for all people at risk of malaria. ‘Across sub-Saharan Africa, the proportion of people sleeping under treated nets has nearly doubled over the last 5 years’, she said.

The report spotlights a number of positive trends, particularly in sub-Saharan Africa, the region that carries the heaviest malaria burden. It shows that, in many  countries, access to disease-cutting tools is expanding at a rapid rate for those most in need.

Although excellent progress has been made, in 2015 there was still a global tally of 212 million cases of malaria and 429 000 deaths. Gaps in coverage are reported for key interventions such as bed nets and in-door residual spraying, with around 43% of the population in sub-Saharan Africa still unprotected.

The progress of the past 15 years is threatened by the rapid development and spread of mosquito resistance to insecticides. Antimalarial drug resistance could also jeopardize recent gains.

Welcoming the Report, IVCC CEO, Dr Nick Hamon said, ‘The significant gains in the battle against malaria are to be applauded, but the battle is far from over. Vector control is now widely recognised as a key player in the battle and IVCC is deeply committed to ensuring it delivers the new vector control tools needed to ultimately defeat this insidious disease.’

Find out more about the World Malaria Report 2016 here.

IVCC is to receive new funding of £25million from UKAID for its work developing new anti-malarial insecticides. The announcement was made by the Secretary of State for International Development, The Rt Hon Priti Patel MP, at the launch of the WHO World Malaria Report 2016 in London.

‘We are here to celebrate the continuing progress in the battle against malaria, and the leadership role the UK is playing as part of the global effort,’ she said. ‘But progress is now overshadowed by the big issue of drug resistance and insecticide resistance. So it is imperative that the world continues to affirm its commitment to tackling malaria today, and to meeting that critical target agreed last year, of reducing the malaria burden by a further 90% by 2030.’

‘The UK has been at the forefront of the fight against malaria for many years, but we must keep up the momentum. Long lasting insecticide treated nets and indoor residual spraying of homes have had a major impact in the fight against malaria. With our support, IVCC are on track to deliver three new active ingredients to the market by 2022.’

Thanking UKAID, IVCC CEO, Dr Nick Hamon said, ‘This is absolutely wonderful news. This grant will result in significant impact through the creation of a toolbox of novel vector solutions. We thank the staff at UKAID for their outstanding support over the past three years and look forward to working with them over the next four years and beyond. IVCC has a very strong pipeline of potential products, with one new product in particular (Actellic CS), co-developed with Syngenta, saving lives and having a significant impact in Africa’.

Read the full speech of the Secretary of State here

IVCC would be nothing without our industrial partners.

We have a great mission— to save lives by preventing malaria with repurposed or new classes of insecticides that kill the mosquitoes that transmit malaria.

Since 2005 we’ve worked with a great cloud of scientists, researching millions of chemical compounds to find the best ones to stop malaria. We’ve helped apply the best minds in chemistry, reformulations, and all kinds of other scientific magic that I know little about.

Except that it works, and it is working, and we’re nearly there with the new active ingredients that will transform malaria vector control. Yes, and save lives. Millions of lives. Young children and pregnant women will no longer die from this preventable disease.

So, it’s very appropriate on World Malaria Day, to say thank you to all IVCC’s industrial partners. That includes scientists at BASF, Bayer, Sumitomo, Syngenta and Mitsui. We couldn’t do it without your quiet, selfless dedication to solve a critical and global public health crisis. In the battle against malaria I think you are truly heroes.

Thank you for everything you do. You are truly making the world a better place.

Watch the film Heroic Chemistry 

IVCC this week attended Syngenta’s 2017 Good Growth Plan event in Brussels, Belgium.  Dr Nick Hamon, CEO of IVCC was interviewed about their partnership programme and spent time with Syngenta CEO Erik Fyrwald.  Earlier in the day, David Maguire, IVCC’s NgenIRS Director presented to over 200 invited guests providing an insight on how Syngenta’s malarial insecticide Actellic©CS300 is being used, with the support of IVCC and its funder UNITAID, to deliver next generation indoor residual spray programmes across sub-Saharan Africa.

Nick Hamon, CEO of IVCC said: “Field trial partners in Africa play an essential role in the testing of novel vector control products being developed and one of the most important elements of the field trial is the quality of the data generated, as this is the key to establishing the true nature of the products being tested.”

Since 2000, IVCC, in partnership with the London School of Hygiene & Tropical Medicine, has been working to strengthen the quality and reliability of data generated by African vector control field trial sites.  This work has included the development of Standard Operating Procedures (SOPs), the auditing of facilities, and follow-up Good Laboratory Practice (GLP) training workshops.

An important element of IVCC’s GLP rollout programme has also been its funding of infrastructure improvements including buildings and equipment at its collaborating trial sites.  This capacity building is establishing a network of facilities in Africa that can generate testing data on vector control products of the highest standard.

Professor Franklin Mosha, Test Facility Manager for the KCMUCo facility said: “Reaching this important milestone is a major achievement for IVCC and KCMUCo, and credit is due to all of the staff in Moshi who have implemented enormous changes in relation to their facilities, working practices and culture over a relatively short but intense period of time.”

Nick Hamon, CEO of IVCC added: “A future network of GLP certified trials sites across Africa will allow manufacturers of vector control products to generate their own efficacy data for inclusion in their product dossiers submitted to the WHO product evaluation process. This represents a major step forward for vector control product testing, which will be of major importance in delivering the IVCC mission and malaria elimination in the future.”

Six further IVCC collaborating trials sites are now planning their GLP studies and will be submitting their applications for OECD GLP certification through SANAS.

Notes to journalist

IVCC

IVCC is a non-profit public-private partnership, which aims to save lives, protect health, and increase prosperity in areas where disease transmitted by insects is endemic. It brings together the best minds to develop new solutions to prevent disease transmission. By focusing resources and targeting practical scientific solutions, it accelerates the process from innovation to impact.  IVCC has several novel public health insecticide active ingredients at the point of final development, for delivery in about 2022.  Although primarily targeted at malaria vectors, these insecticides will have application to other NTDs.  IVCC is also currently exploring control of mosquitoes that transmit outdoors and during the day.